Showing 5821-5830 of 7140 results for "".
- La Roche-Posay and George Washington University Publish International Study on Sun Protection Behavior and Skin Cancer Awarenesshttps://practicaldermatology.com/news/la-roche-posay-and-george-washington-university-publish-international-study-on-sun-protection-behavior-and-skin-cancer-awareness/2458327/A large international survey on sun exposure behaviors and skin cancer detection found there are many imperfections and geographical inequalities in primary and secondary prevention of skin cancer. This information could help inform future awareness campaigns developed to address the global need
- Skin Cancer Foundation: Bill Ridenour Is New Senior Director of Partnership Developmenthttps://practicaldermatology.com/news/skin-cancer-foundation/2458333/The Skin Cancer Foundation has appointmented Bill Ridenour to the role of senior director of partnership development. Ridenour’s career has spanned over 30 years in the advertising industry and this new position marks a switch to the nonprofit sector. Prior to his appointment, Ridenour
- National Psoriasis Foundation Awards 2016 Grants and Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-2016-grants-and-fellowships/2458334/The National Psoriasis Foundation (NPF) awarded more than $1.9 million in research funding in 2016, including 23 new projects from around the world. Established and emerging scientists received awards for their innovative work in advancing the research of p
- Oculus Innovative Sciences' SebuDerm Gel Availablehttps://practicaldermatology.com/news/fda-clears-oculus-innovative-sciences-sebuderm-gel/2458340/Oculus Innovative Sciences, Inc.’s Microcyn-based SebuDerm Gel is available in the US. As a prescription product, SebuDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrhea and seborrheic dermatitis. The gel, which
- Sandoz Acquires AmLactin Brandhttps://practicaldermatology.com/news/sandoz-acquires-amlactin-brand/2458342/Sandoz today announced that it has acquired the AmLactin® family of skin care brands from Minnesota-based pharmaceutical company Upsher-Smith Laboratories, Inc.
- Carmex Rolls Out New Comfort Care Lip Balmshttps://practicaldermatology.com/news/carmex-rolls-out-new-comfort-care-lip-balms/2458343/Harsh winter weather can wreak havoc on the lips, leaving them dry, chapped and irritated. New CARMEX COMFORT CARE™ lip balms can help, says New York City dermatologist Neil Sadick, MD at a media event. Launched in late 2016, the new line is fo
- FDA Approved Eucrisa (Crisaborole) for ADhttps://practicaldermatology.com/news/fda-approved-eucrisa-crisaborole-for-ad/2458344/The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) i
- Points Group and Dermatology Authority Launch the Derm Toolkit: A Revolutionary Service and Product Line for Dermatology Practiceshttps://practicaldermatology.com/news/points-group-and-dermatology-authority-launch-the-derm-toolkit-a-revolutionary-service-and-product-line-for-dermatology-practices/2458346/Points Group and Dermatology Authority are excited to announce the launch of the Derm Toolkit, an online portal that provides dermatology practices with a comprehensive set of tools and services to operate more effectively and grow their practices. Over the next four months, the
- Valeant Appoints William D. Humphries As EVP, Dermatologyhttps://practicaldermatology.com/news/valeant-appoints-william-d-humphries-as-evp-dermatology/2458348/Valeant Pharmaceuticals International, Inc. appointed William D. Humphries as Executive Vice President, Dermatology, effective January 2, 2017. Mr. Humphries will join Valeant's Executive Committee, reporting directly to
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad